Rich evidence has highlighted that stimulation of g-amino-butyric acid (GABA) B receptors increases the occurrence of spike-and-wave discharges (SWDs), the electroencephalographic (EEG) landmark of absence epilepsy (AE). Recent findings suggest that the outcomes of GABA B activation in vivo are contingent on the chemical characteristics of the agonist. In particular, the endogenous ligand ghydroxybutyrate (GHB) and its precursor g-butyro-lactone (GBL) have been shown to elicit different effects than the prototypical GABA B agonist baclofen. In view of these premises, the present study was aimed at the characterization of the effects of baclofen (0.5-10 mg/kg, i.p.) and GBL (5-100 mg/kg, i.p.) on the spontaneous SWDs and locomotor activity of DBA/2J mice.
While both baclofen and GBL dose-dependently increased SWDs episodes, high doses of the latter (100 mg/kg, i.p.) reduced the occurrence of these phenomena and increased the number of isolated spikes. Interestingly, both compounds elicited a dose-dependent reduction of locomotor activity, in comparison with their vehicle-treated controls. The GABA B selective antagonist, SCH50911 (50 mg/kg, i.p.), reversed the changes in SWD occurrence and locomotion induced by baclofen and GBL, but failed to elicit intrinsic effects on either paradigm. These results indicate that GABA B receptor signaling might exert differential effects on SWDs in DBA/2J mice.
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numerous experimental advantages: first, it exhibits a greater ability to cross the blood-brain barrier 12 ; second, it is inherently inactive and rapidly converted to GHB after parenteral administration 13 ; finally, it shows a better dissociation between EEG abnormalities and alterations of thermoregulation than its metabolite.
14 To understand whether the differences between baclofen and GBL may be actually mediated by GABA B receptors, the effects of the two compounds were also studied in presence of a GABA B selective antagonist, SCH50911.
Materials and methods

Animals
Juvenile (4-5 weeks old) male DBA/2J mice (Harlan, Como, Italy) (n = 131; weight: 25-30 g each) were housed four per cage under a 12 h light/dark cycle (light on at 8:00 AM), in conditions of constant temperature (21 AE 2 8C) and humidity (60%), with food and water ad libitum. All experimental procedures were approved by the local ethical committee and conducted in conformity with the University of Cagliari guidelines. The experimental preparation followed the methods previously described. 5 Briefly, mice were anesthetized and placed in a stereotaxic apparatus (David Kopf, mod. 900). Each skull was exposed and perforated in four points, located above both sensorimotor cortices (FPr and FPl), 0.5 mm anterior to the bregma (Cz), and over the cerebellum (G2). A four-pin male socket was positioned into the holes, secured to the skull with epoxy resin and covered with acrylic cement to improve retention.
Drugs
The following drugs were used in this study: GABA B receptor agonists baclofen and g-butyro-lactone (GBL), as well as GABA B antagonist SCH50911 (Tocris Cookson, UK). All drugs were dissolved in saline 0.9% and administered intraperitoneally (i.p.) in an injection volume of 10 ml/kg. The dose ranges of baclofen and GBL were selected so as to have similar efficacy, based on the comparison of their ED 50 values 8 and on preliminary observations by our group.
EEG recordings
EEG recordings were acquired on a portable EEG polygraph (BQS 98 System Micromed, Mogliano Veneto, Italy), and the Electrode impedance was maintained at <5 kV. Digital EEG signals were filtered with elliptical filter banks to obtain the optimal resolution of broadband parameters. Given that synchronization analysis requires a zero-phase filtering distortion, data were further processed by forward-backward filtering. 15 The off-line SWDs analysis was accomplished separately by trained researchers blinded to this experimental phase of the study. In addition to visual inspection, SWDs morphology was assessed by means of a customized algorithm aimed at detecting significant variations occurring under a pre-settled threshold, based on the analysis of the fractal dimension of the EEG signal. 16 DBA/2J mice exhibited an EEG pattern with 12-18 Hz lowmedium voltage background activity mixed with 6-12 Hz highvoltage SWDs events. To maintain normality and homoscedasticity criteria in the sampled population, experiments were performed on the basis of SWD event frequency in the baseline EEG recording by selecting animals displaying between 6 and 25 SWDs/30 min (with a median value of 13 in the overall tested population) while mice showing very low or very high number of SWDs (more than two standard deviations above or below group mean values) were excluded from the study. Each treatment group consisted of 5-7 animals, and each animal was injected with only one dose throughout the study. Recordings started between 8 and 10:30 AM, and were analyzed in two blocks, respectively before and after drug administration. The first block, lasted 60 min (two 30-min intervals) and was used to monitor the baseline conditions of each animal. In this phase of EEG recording, DBA/2J mice exhibited characteristic spontaneous short-lasting spiking activity bursts (4-12 s duration and 250-550 mV amplitude), superimposed to baseline activity of 50-120 mV EEG rhythms.
The second block lasted 90-150 min (three to five 30-min intervals) and was used to assess the effects of the treatment. SWD analysis was based on their number (calculated as the average number of events occurring in a 30-min interval) and mean duration for pre-and post-injection blocks were calculated.
Episodes of drowsiness and sleep were discarded, as previous studies in other rodent models of AE showed relevant SWDs variations during sleep. 17 
Locomotor activity
We tested the impact of GABA B ligands on the locomotor activity in a different group of DBA/2J mice. The motility cages (Omnitech Digiscan Animal Activity Monitor, Columbus, OH, USA) featured 2 sets of 16 photocells located at right angles to each other, projecting horizontal infrared beams 2.5 cm apart above the cage floor. After a 30-min acclimatization period in the apparatus, each animal was injected and its locomotor activity was studied for further 90 min. Locomotion was measured with the horizontal activity counts in 10-min intervals.
Statistical analyses
Number and mean duration of SWDs were analyzed by 2-factor ANOVAs, with treatment dose as an independent factor and blocks (pre-and post-injection) as repeated measures. Locomotor activity was analyzed by 2-factor ANOVAs, with dose as independent factor and time (consecutive 10-min intervals). Post hoc comparisons were performed with Tukey's test. Alpha was set at p < 0.05.
Results
Effects of baclofen on SWD
In the first experiment (Fig. 1) , the effects of baclofen (0.5-10 mg/kg, i.p.; n = 5-7/group) on SWD number and mean duration were tested and compared with both vehicle-treated mice and their individual baseline values. Baclofen was found to exert a significant main effect on SWDs occurrence [F(1,29) = 38.44, p < 0.001]. The analysis of dose Â block interactions also revealed a significant effect [F(5,29) = 10.63, p < 0.001]. Post hoc comparisons further established that the doses of 2.5, 5 and 10 produced a significant increase in comparison to their baseline and to vehicletreated subjects. Conversely, baclofen did not produce any significant change in SWD duration (Fig. 1d) at any dose tested. No difference in baseline SWD number or duration was found.
Effects of baclofen on locomotor activity
As changes in the number of SWDs may reflect behavioral alterations (such as profound sedation), we evaluated the behavioral impact of baclofen (2.5-10 mg/kg, i.p.) on the motor activity of a different group of DBA/2J mice (n = 5/group). The evaluation of the effects of baclofen (2.5-10 mg/kg, i.p.) on locomotor activity revealed a main dose effect [F(3,16) = 5.91, p < 0.01], which was found to reflect a significant difference between the animals treated with vehicle and those injected with the 10 mg/kg dose of the GABA B agonist (p < 0.01, Tukey's test). Furthermore, we detected a main effect for time [F(9,144) = 55.09, p < 0.001] and a significant dose Â time interaction [F(27,144) = 2.08, p < 0.01]. Post hoc scrutiny of this effect revealed that the 10 mg/kg dose of baclofen induced a significant reduction in activity at 30 and 40 min after injection (Fig. 2) . None of the other doses triggered significant alterations in locomotor activity in comparison with vehicleinjected animals.
Effects of GBL on SWD
The third experiment was designed to test the effect of different GBL doses (5-100 mg/kg, i.p.; n = 5-7/group) on SWD number and mean duration. GBL significantly increased SWD number [F(1,23) = 20.09, p < 0.001]. Further analysis revealed that such effect was dose-dependent [F(4,23) = 7.50, p < 0.001] and significant at the intraperitoneal doses of 50 (p < 0.05) and 100 mg/kg (p < 0.01) (Tukey's test) (Fig. 3) . Interestingly, GBL effects on SWD duration produced a reduction close to significance threshold [F(1,23) = 4.00, p = 0.056]. Further analysis revealed that such effect was significant at the dose of 100 mg/kg (i.p.) [dose Â block interaction: F(4,23) = 7.50, p < 0.001, p < 0.01 for 100 mg/kg dose, Tukey's test]. No difference in baseline SWD number or duration was found.
Effects of GBL on locomotor activity
We then tested the impact of GBL (50-100 mg/kg, i.p.; n = 5/ group) on locomotor activity, with a design mirroring the experiment on baclofen. ANOVA detected main effects for both 
Effects of SCH50911 on the effects of baclofen and GBL
In the next experiment, we verified whether the variations in SWDs and EEG produced by baclofen (5 mg/kg, i.p.) and GBL (100 mg/kg, i.p.) were reversed by pretreatment with SCH50911 (50 mg/kg, i.p.) (Fig. 5) . In a separate experiment, we verified the impact of SCH50911 on the locomotor effects of baclofen (10 mg/kg, i.p.) and GBL (100 mg/kg, i.p.). As expected, the GABA B antagonist did not inherently modify the locomotor activity, and completely countered the effects of both agents (data not shown).
Discussion
The main result of the present study is that both baclofen and GBL, two GABA B receptor agonists, significantly increase SWD expression in DBA/2J mice. Notably, while baclofen and low doses of GBL enhanced the occurrence of SWDs without affecting their duration, high doses of GBL shortened the average duration of these phenomena. The selective GABA B antagonist SCH50911 prevented the increase in SWD number induced by baclofen and GBL, confirming that both compounds produced their effects through activation of GABA B receptors. Furthermore, the intermediate doses of baclofen (2.5-5 mg/kg) and GBL (50 mg/kg) increased the number of SWDs without eliciting any significant effect on locomotion, suggesting that the reported alterations in SWD manifestations are not completely secondary to behavioral changes.
Our findings are consistent with previous evidence, highlighting a key role for GABA B receptors in SWDs modulation. Indeed, GABA B receptor activation exacerbates SWDs in AE rodent models. 18, 19 The different impact on SWD modulation elicited by equipotent doses of baclofen and GBL is also in line with recent lines of evidence documenting that their effects, albeit both mediated by GABA B receptors, are underpinned by partially divergent mechanisms. [7] [8] [9] The distinctive effects of the two GABA B agonists have been posited to reflect separate contributions from different receptor subpopulations. 8, 9 Although the evidence on GABA B subtypes is still inconclusive, 22 converging lines of research support their existence and indicate that they may exert different roles in relation to their different regional distribution and intracellular segregation. [23] [24] [25] [26] Thus, variations in affinity for different isoforms of GABA B subunits (or their combination) may condition the outcomes of different GABA B ligands in AE murine models. 27 This conceptual framework may also help understand the different profile of Fos expression enkindled by GHB and baclofen. 28 In a well-validated AE model, lethargic (lh/lh) mice, GABA B receptors modulate absence expression based on their regionalspecific sensitivity in thalamo-cortical nuclei, as well as ventral thalamic nuclei and nucleus reuniens. 29 Indeed, the effects of high GBL doses on SWD duration might also indicate a preferential action of this compound on cortical networks, as suggested by previous studies. 25, 30 Conversely, baclofen increased SWDs without altering them, suggesting that this compound may activate mainly thalamo-cortical GABA B receptors. The functional divergence between GHB and baclofen has been suggested to reflect specific interactions between specific GABA B receptor variants and the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. 31 This possibility is particularly intriguing, in view of the role of NMDA receptors in the initiation and maintenance of SWD, [32] [33] [34] as well as the altered responsiveness of NMDA receptors in DBA/2J mice. 35 An alternative possibility to account for the different effects of baclofen and GBL may reflect the specific contribution of GHB on its own receptors, 36, 37 which may in turn modulate GABA release and alter the effects of GABA B receptor activation. 38 The behavioral effects of baclofen and GBL on spontaneous locomotor activity followed a typical dose-and time-dependent fashion, with a substantially equivalent pattern in comparison to vehicle-treated controls. The shorter time of maximal action of GBL (20-40 min) in comparison to baclofen (30-50) reflects previous observations on the behavioral impact of these two compounds 8 and is likely to signify GHB's brief half-life. 39 The hypomotility observed in this study is in keeping with previous results on the effects of both GABA B agonists. 40, 41 It is worth noting the dosages of GBL and baclofen have been shown to be in a cataleptogenic range in mice, 8 suggesting that the near-total lack of spontaneous activity induced by both agents may have reflected extrapyramidal deficits, plausibly due to the impingement of common mechanisms. Our experiments have shown that the profile of SWD modulation by GABA B ligands in DBA/2J exhibits a number of atypical features. Firstly, GABA B agonists increased only the number, but not the duration, of SWD bursts. 42 Secondly, SCH50911 did not suppress SWDs in DBA/2J mice. Particularly this last finding is at variance with a large body of evidence documenting that GABA B blockade reduces AE manifestations and SWDs in AE models. [43] [44] [45] [46] [47] [48] By definition, the intrinsic effects of a receptor antagonist reflect a tone of the endogenous activator; therefore, the lack of effect of SCH50911 in DBA/2J mice is likely to indicate that, unlike other AE models, these animals may not have a physiological ''GABA B tone''. While the present study cannot help identify the mechanisms underpinning such a critical difference, it is tempting to speculate that this phenomenon may be connected to our previous finding of a reduced expression of GABA B receptor in the cortex. 4 Of note, this evidence is in seemingly striking contrast with the up-regulation of GABA B receptors in other models of AE. 25 Further studies are warranted to establish the specific role of GABA B receptors in the circuitry underpinning SWD in DBA/2J mice and the functional valence of the variations in GABA B receptors in this strain. Irrespective of these considerations, the present findings on DBA/2J mice warrant further studies on the role of GABA B receptor in SWD modulation, and suggest that distinctive actions on GABA B signaling might differentially regulate the expression of SWDs.
